Tarceva® (erlotinib) Now Only Available Through Limited Distribution: Onco360® Selected as Network

NEW YORK - July 1, 2013 - PRLog -- Media Contact:  Amvrosios Ioannidis
Onco360^®
P:  646-356-7705
M: 516-492-2557
E: amvrosiosi@Onco360.com

Tarceva^® (erlotinib) Now Only Available Through Limited Distribution: Onco360^® Selected as a Network Pharmacy Provider;
Patient Transfer Process Available to Non-Network Pharmacies  

New York – Effective today, the oral cancer medication Tarceva^® (erlotinib), will no longer be available through retail pharmacies.  The treatment will only be available through a limited distribution network of specialty pharmacies, and Onco360 is proud that its OncoMed dispensing pharmacies have been selected as part of this high-performance network.

Onco360 has developed a Transfer Process for Tarceva patients in order to provide seamless clinical & dispensing support to any patients currently receiving therapy from a pharmacy that will no longer have access to the treatment.  Anyone interested in transferring Tarceva patients to Onco360 should call 877-662-6633.

Tarceva is approved as a maintenance therapy for patients with Advanced Non-Small Cell Lung Cancer (NSCLC), as well as a second or third-line therapy for Advanced NSCLC¹.

“The Onco360 model of oncology-focused pharmacy care continues to resonate with oncologists and patients, and we are very pleased that manufacturers continue to acknowledge that by including Onco360 in their limited distribution networks.” said Ron Bookman, Senior Vice President of Trade Channel Strategy Relations for Onco360.  

“As a company, we are committed to offering our customers the most comprehensive access to oral, injected, and infused oncology pharmaceutical medications.  Our limited distribution product portfolio is a testament to not only the clinical and dispensing Oncology Pharmacy platform we have built, but to the excellent work and support our company employees strive to provide our customers; from oncologists and hospitals, to NCCN Centers of Excellence, manufacturers, and most importantly, patients.”

The Company’s patient transfer process is committed to providing non-network pharmacies a transition that ensures their Tarceva patients will experience no lapses or clinical gaps in treatment.  Onco360 has a team standing by at 877-662-6633 to handle transfer requests.

For more information about Onco360 please visit Onco360.com (http://www.Onco360.com).

1.  http://www.tarceva.com Accessed June 30, 2013

About Onco360^®:

With executive offices in New York City, Onco360 is the largest independent Oncology Pharmacy in the country.  Onco360 was founded in 2003 as OncoMed, The Oncology Pharmacy, to serve the specialized needs of oncology-treating physicians, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers.  The company’s clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients.  In its focus to bring together the stakeholders involved in the cancer treatment process, Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology.  Onco360 dispenses through its network JCAHO-accredited OncoMed Pharmacies.

Onco360^® | 410 Park Avenue, Suite 820 | New York, NY 10022